Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Flying Blind: Learning to Live Without Physician Prescribing Data

This article was originally published in RPM Report

Executive Summary

Physicians aren't happy about the prescribing information companies use to help develop sales and marketing activities, and they're doing something about it. Policies adopted by medical professionals--and legislation moving at the state level--threaten to cut off marketers' access to information about who prescribes their products. Pharma companies better prepare to adapt to new ways of tracking sales.

You may also be interested in...



Data Mining Case Struck Down by Supreme Court; IMS Prepares for Future Battles

When the Supreme Court threw out a Vermont law that prevented pharmaceutical companies from using physician prescribing data for marketing purposes, the unexpectedly broad opinion was cheered by Big Pharma and data miners alike. But IMS Health is already gearing up for the next data mining battle. And this time, the company says, the fight will be about protecting patient privacy.

REMS Audits: Legal and Practical Challenges

Biopharma companies have been vociferous in their objections to FDA's proposal that they audit other sectors of the health care system to determine the success of REMS once drugs get into commercial distribution. Audits would clearly be a large undertaking for biopharma companies. But even if they cannot cut off FDA's interest in an added audit function, the complaints may lead to a positive outcome: getting FDA on the side of more efforts by biopharma companies to track data on their products.

Waking Up to REMS (Part 3): Redefining Marketing

FDA's new post-marketing safety authorities place unprecedented burdens on pharmaceutical marketers. But they do something else: redefine a favorite target of industry critics as a regulatory requirement rather than a suspicious activity.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS080164

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel